BACKGROUND: The incidence and mortality of lung cancer are increasing every year, making it the primary cause of cancer-related fatalities globally. Upregulation of C1qtnf6 expression is observed in various human cancers. This study aimed to explore the function of C1qtnf6 in lung adenocarcinoma (LUAD) progression. METHODS: We used The Cancer Genome Atlas (TCGA) dataset to analyze data on lung cancer. The relationship between C1qtnf6 expression and treatment outcomes in patients with LUAD was evaluated using a Kaplan-Meier survival analysis. The receiver operating characteristic (ROC) curve was analyzed to ascertain the diagnostic value of C1qtnf6 in LUAD. Additionally, we performed a correlation analysis to investigate the association between the transcription of C1qtnf6 and inflammation in LUAD. To create LUAD cell lines with reduced C1qtnf6 expression, C1qtnf6 was knocked down, and several in vitro analyses were conducted to determine how C1qtnf6 knockdown affected the proliferation and apoptosis of LUAD cells. Furthermore, the relationship between C1qtnf6 and Interleukin-10 (IL-10) was verified. Using the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis and Gene Ontology (GO) studies, we further examined the impact of C1qtnf6 knockdown on the biological behavior of LUAD cells. RESULTS: TCGA dataset analysis revealed that C1qtnf6 expression was much higher in LUAD tissues than in the adjoining normal tissues. Correlation analysis revealed a relationship between C1qtnf6 expression and immune cell infiltration in LUAD. It has been demonstrated that C1qtnf6 expression is closely associated with the tumor immunological milieu, immune checkpoint blockade (ICB), and response to cisplatin treatment. In vitro tests revealed that C1qtnf6 knockdown reduced IL-10 levels, accelerated apoptosis, and hindered the growth of LUAD cells, thus indicating a possible link between C1qtnf6 and inflammation. CONCLUSION: Our results show that C1qtnf6 may be useful as a prognostic indicator for LUAD.
C1qtnf6 Expression as a Prognostic Biomarker and Therapeutic Target in Lung Adenocarcinoma: Implications for Immune Infiltration and Tumor Progression.
C1qtnf6 表达作为肺腺癌的预后生物标志物和治疗靶点:对免疫浸润和肿瘤进展的影响
阅读:13
作者:Li Qincai, Zhang Hua, Yun-Liu Hai, Zheng Peifeng, Xu Xiaogang
| 期刊: | Cancer Reports | 影响因子: | 1.900 |
| 时间: | 2025 | 起止号: | 2025 Jun;8(6):e70205 |
| doi: | 10.1002/cnr2.70205 | 研究方向: | 肿瘤 |
| 疾病类型: | 肺癌 | ||
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
